Evaluation of the Efficacy of Almotriptan and Ubrogepant for the Acute Treatment of Migraine
Status:
Not yet recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
In a real-world population of adults with migraine, the investigators would like to
investigate whether 12.5 mg almotriptan is non-inferior to 50 mg ubrogepant in terms of pain
freedom at 2 hours after drug intake.